Why the FDA Erased the HRT 'Black Box' Warning in 2026 — and the One Risk That Stayed

For more than twenty years, menopausal hormone therapy carried the strongest warning the FDA can print — a black box linking it to heart disease, breast cancer, and dementia. In February 2026 the agency removed those statements from the first six products. Women deserve a clear read on what that does and does not mean.

Key Takeaways

• In February 2026 the FDA approved labeling changes removing cardiovascular, breast-cancer, and dementia warnings from the boxed section of six menopausal hormone therapy products (FDA, 2026).
• The first products were Bijuva, Divigel, Cenestin, Enjuvia, Prometrium, and Estring; more are expected as 29 manufacturers submitted updates (FDA, 2026).
• The endometrial (uterine cancer) warning stays on systemic estrogen-alone products (FDA, 2026).
• The change reflects newer evidence that, for most healthy women under 60 or within 10 years of menopause, benefits for symptoms often outweigh risks (FDA; Menopause Society, 2026).

What Exactly Did the FDA Change?

On February 12, 2026, the FDA approved new labeling for six hormone therapy products that removed the boxed warnings about cardiovascular disease, breast cancer, and probable dementia (FDA, 2026). Those warnings traced back to the 2002 Women's Health Initiative, whose average participant was about 63 — well past typical menopause onset. The FDA's own leaders concluded the old warnings no longer matched today's science or today's patients. The move followed an expert review that began in late 2025.

Citation capsule: The February 2026 FDA labeling change removed cardiovascular, breast-cancer, and dementia boxed warnings from six hormone therapy products after a review found the original alarms no longer fit current evidence for appropriately selected patients (FDA, 2026).

This reversal parallels the GLP-1 suicide warning removal — both show labels catching up to data.

Which Products Changed First?

The first six were Bijuva (estrogen-progestogen), Divigel and Cenestin and Enjuvia (estrogen-alone), Prometrium (progesterone), and Estring (vaginal estrogen) (FDA, 2026). Because 29 manufacturers submitted proposed updates, more products are expected to be relabeled through 2026. The key distinction: this was a labeling correction, not a blanket instruction that every woman should start hormones.

Citation capsule: Bijuva, Divigel, Cenestin, Enjuvia, Prometrium, and Estring were the first six products relabeled in February 2026, with additional products anticipated as manufacturers submit updates (FDA, 2026).

Our estrogen and perimenopause article weighs the personal risk-benefit question in depth.

What Did NOT Change?

The endometrial cancer warning stays on systemic estrogen-alone therapy, because unopposed estrogen still carries that risk for women with a uterus (FDA, 2026). Women with a uterus still need progesterone protection, and anyone with a history of breast cancer, blood clots, stroke, or certain other conditions remains a poor candidate. The label removal is not a green light for self-prescribing or for starting hormones decades after menopause.

Citation capsule: The uterine (endometrial) cancer warning remains on systemic estrogen-alone products, and women with a uterus still require progestogen protection; the 2026 change did not remove all cautions (FDA, 2026).

For symptom-specific help, see Veozah for hot flashes and HRT feeling worse first.

Who Benefits Most Now?

The modern framing favors starting before age 60 or within 10 years of menopause, when benefits for hot flashes, sleep, vaginal symptoms, and bone protection tend to outweigh risks for healthy women (FDA; Menopause Society, 2026). About 40% of women with troublesome hot flashes and night sweats go untreated, and the label change aims to close that gap by letting clinicians counsel from clarity rather than fear (Menopause Society, 2026).

Citation capsule: Current guidance frames hormone therapy as generally favorable for healthy women under 60 or within 10 years of menopause, a window when symptom benefits often outweigh risks and where undertreatment has been common (FDA; Menopause Society, 2026).

Our perimenopause and cardiovascular risk article covers the heart-angle context.

Frequently Asked Questions

Does the black box removal mean HRT is safe for everyone?

No. The endometrial warning stays, and women with certain histories (breast cancer, clots, stroke) remain poor candidates (FDA, 2026).

Which products were relabeled first?

Bijuva, Divigel, Cenestin, Enjuvia, Prometrium, and Estring, with more expected through 2026 (FDA, 2026).

Should I start hormones at 65?

Benefit-risk is most favorable under 60 or within 10 years of menopause; later starts need careful individual assessment (FDA; Menopause Society, 2026).

Is vaginal estrogen affected?

Estring was among the first relabeled, and vaginal estrogen's local benefits are well supported, but discuss your history with your clinician (FDA, 2026).

Conclusion

The 2026 FDA labeling change strips the scariest warnings from menopausal hormone therapy for appropriately selected women, correcting a two-decade-old overcorrection rooted in older, older-average data. The endometrial warning stays, and personal history still rules. Read the change as permission for an honest conversation with your clinician — not as a prescription.

Sources

• U.S. FDA. FDA approves labeling changes to menopausal hormone therapy products. February 12, 2026. Retrieved 2026-08-11. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
• The Menopause Society. Comment on the FDA announcement on hormone therapy, 2026. Retrieved 2026-08-11. https://menopause.org/